デュシェンヌ型筋ジストロフィー及びベッカー型筋ジストロフィー治療薬の世界市場:画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

【英文タイトル】Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
デュシェンヌ型筋ジストロフィー及びベッカー型筋ジストロフィー治療薬の世界市場:画期的医薬品の市場機会及び商用化 (Code:GBIHC361MR)

【レポートの概要(一部)】

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy – Identifying and Commercializing First-in-Class Innovation

Summary

Highly Innovative and Diverse Pipeline

The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Research’s analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. The strong presence of first-in-class products in the pipeline therefore creates a distinctly different landscape to the market landscape, which relies on symptomatic treatment glucocorticoids. Although Translarna (ataluren) is developed to correct the genetic defects, significant unmet needs remain in the market, as the treatment is applicable to only 10–15% of all DMD cases caused by nonsense mutations.

Despite a strong focus on personalized treatments that treat the genetic cause of the disease in the DMD/BMD pipeline, innovation is also concentrated on novel molecular targets that alleviate the dystrophic pathology regardless of gene mutations, thereby allowing widespread use in contrast to the mutation-specific treatments. These therapies are expected to be used alongside primary treatment to repair the mutated gene, halt muscle degeneration, and improve life expectancy of patients in the future market.
Strong Alignment of Innovation to Genetics and Disease Processes in Early Pipeline

DMD, and BMD, which is the less severe form, are neuromuscular diseases caused by heritable mutations in the single dystrophin gene, which ultimately lead to progressive muscle weakness and degeneration due to destabilization of the sarcolemma (muscle cell membrane) and the resultant loss of muscle integrity. However, increasing evidence suggests that multiple secondary pathological mechanisms, rather than dystrophin deficiency alone, cause or contribute to the pathological features of DMD/BMD and drive disease progression. This further substantiates the need for better understanding of the downstream events of dystrophin deficiency to enable the identification of more potential molecular targets that in turn could be translated into disease-modifying treatments.

Our proprietary analyses show that the 13 first-in-class targets differ substantially in terms of clinical and commercial potential based on how well their functional roles align to the disease pathophysiology and the strength of evidence in Preclinical studies. Some molecular targets are therefore considered more promising than others due to a stronger potential to be translated into novel treatments. The most promising targets provide a strong scientific rationale to support their therapeutic development, as indicated by substantial improvement in both muscle histopathology and function in vivo across different animal model systems.

Analysis also indicates opportunities for some of the first-in-class DMD/BMD targets to be repositioned to other MDs, although this is expected to be challenging given the currently limited understanding of the common molecular processes defected across multiple types of MD.

Numerous Investment Opportunities in Deals Landscape

Strategic consolidation is relatively uncommon in the DMD/BMD market, with 15 licensing agreements and 18 co-development deals between 2006 and April 2015. Supported by findings from the industry-wide analysis, there is a tendency for first-in-class DMD programs to attract higher deal values than non-first-in-class programs, thus highlighting their commercial attractiveness. Despite the high-risk profile of first-in-class products, they have greater potential to revolutionize or improve therapeutic options, meaning that identifying promising first-in-class compounds early in development offers the greatest potential commercial benefit to pharmaceutical companies.

With 36 first-in-class products that are currently in development having not yet been involved in a licensing or co-development deal, there are numerous opportunities for in-licensing or co-development in this indication

Scope

The report analyzes innovation in DMD/BMD in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in DMD/BMD and pinpoints opportunities for in-licensing.
The report covers and includes –
– A brief introduction to DMD/BMD, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms
– The changing molecular target landscape between market and pipeline and particular focal point
.....


【日本語概要(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポートの目次(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Highly Innovative and Diverse Pipeline 4
2.2 Alignment of Innovation to Genetics and Disease Processes 4
2.3 Deals Landscape Present Substantial Investment Opportunities 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Epidemiology and Etiology 9
4.2.1 Disease Inheritance 10
4.3 Disease Pathophysiology 10
4.3.1 Hypothesized Pathophysiological Mechanisms of Duchenne Muscular Dystrophy/ Becker Muscular Dystrophy 11
4.3.2 Dysfunction in Regeneration and Development of Fibrosis 13
4.4 Disease Symptoms 13
4.5 Complications and Co-morbidities 14
4.5.1 Respiratory Complications 14
4.5.2 Cardiac Complications 14
4.5.3 Scoliosis 14
4.6 Diagnosis 14
4.7 Disease Staging and Prognosis 15
4.8 Treatment Options 16
4.8.1 Pharmacological Treatments 16
4.8.2 Non-pharmacological Treatments 18
4.8.3 Treatment Algorithm 19
4.9 Overview of Marketed Products 21
4.9.1 Glucocorticoids 21
4.9.2 Translarna (ataluren) 23
4.9.3 Molecule Type and Target Analysis 23
4.10 Current Unmet Needs 24

5 Assessment of Pipeline Product Innovation 25
5.1 Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Pipeline by Molecule Type, Phase and Therapeutic Target 25
5.2 Comparative Distribution of Programs between Duchenne Muscular Dystrophy/Becker Muscular Dystrophy Market, and Pipeline by Therapeutic Target Family 29

6 Signaling Pathways, Genetics and Innovation Alignment 34
6.1 First-in-Class Target Matrix Assessment 34
6.2 Repositioning Potential among Muscular Dystrophies 36

7 First-in-Class Target Evaluation 38
7.1 Pipeline Programs Targeting Sarcospan 38
7.2 Pipeline Programs Targeting Utrophin 40
7.3 Pipeline Programs Targeting Biglycan 43
7.4 Pipeline Programs Targeting Laminin-111 45
7.5 Pipeline Programs Targeting Hematopoietic Prostaglandin D Synthase 48
7.6 Pipeline Programs which Target G Protein-Coupled Receptor Mas 50
7.7 Pipeline Programs Targeting Mothers against Decapentaplegic Homolog 3 52
7.8 Pipeline Programs which Target Myostatin 54
7.9 Pipeline Programs Targeting Dystrophin 56
7.10 Conclusion 59

8 Deals and Strategic Consolidations 60
8.1 Industry-Wide First-in-Class Deals 60
8.2 Licensing Deals 61
8.3 Co-development Deals 66
8.4 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 68

9 Appendix 70
9.1 Abbreviations 70
9.2 References 70
9.3 Contact Us 77
9.4 Disclaimer 77

.....

【日本語目次(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポート販売概要】

■ タイトル:デュシェンヌ型筋ジストロフィー及びベッカー型筋ジストロフィー治療薬の世界市場:画期的医薬品の市場機会及び商用化
■ 英文:Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
■ 発行日:2015年5月1日
■ 調査会社:GBI Research
■ 商品コード:GBIHC361MR
■ 調査対象地域:グローバル

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
デュシェンヌ型筋ジストロフィー及びベッカー型筋ジストロフィー治療薬の世界市場:画期的医薬品の市場機会及び商用化 (Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation / GBIHC361MR)

  • Ecopetrol S.A.:石油・ガスの開発・生産動向及びコスト分析- Q1, 2013
    Ecopetrol S.A. Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Ecopetrol S.A. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key opera …
  • 機能性食品・飲料の世界市場2017-2021
    About Functional Foods and Beverages Functional foods and beverages are those foods and beverages to which special ingredients are added so that they provide additional health benefits. Regular food items such as cereals, bread, yogurts, snacks, and beverages are converted into functional foods by fortifying them with vitamins, herbs, or other nutrient-rich ingredients. The common ingredients that …
  • ブラジル/ロシア/インド/中国の心臓血管モニタリング及び診断装置市場(~2020)
    BRIC Cardiovascular Monitoring and Diagnostic Devices Market Outlook to 2020 Summary GlobalData’s new report, "BRIC Cardiovascular Monitoring and Diagnostic Devices Market Outlook to 2020", provides key market data on the BRIC Cardiovascular Monitoring and Diagnostic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), …
  • Penn West Exploration:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
  • 世界のOSS BSS市場動向(2012-2016)
    TechNavio's analysts forecast the Global OSS BSS market to grow at a CAGR of 16.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing customer base. The Global OSS BSS market has also been witnessing a shift from multiple platforms to a common platform. However, the short life cycle of the product could pose a challenge to the growth of this …
  • 2014年戦略提言:ドイツの血液凝固検査市場
    Complete report $6,100.  DataPack (test volumes, sales forecasts, supplier shares) $3,950.SummaryThis comprehensive report contains 406 pages, 38 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the German coagulation testing market during the next five years.  The report explores business and technol …
  • General Anxiety Disorder:グローバル臨床試験レビューH2, 2013
    General Anxiety Disorder Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “General Anxiety Disorder Global Clinical Trials Review, H2, 2013" provides data on the General Anxiety Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on General Anxiety Disorder. It includes an overview of the trial num …
  • 化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression):治療薬開発パイプライン動向(2015年上半期版)
    Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparati …
  • スペインの分子診断・NAT市場2014
    This report provides:Five-year sales forecasts for the Spanish Molecular Diagnostics market, including:              -          Infectious Diseases             -          Cancer     …
  • クラウド侵入検知・防止システム(IDP)の世界市場2016-2020
    About Cloud Intrusion Detection and Prevention Increasing cases of cyber attacks have compelled enterprises to increase their spending on IT infrastructure to prevent theft of data. IDSs identify malicious activities over the network and intrusion prevention systems (IPSs) prevent data modification or unauthorized access. IDSs and IPSs include hardware, software, and services. IDS is a passive mon …
  • 世界の腎除神経装置(Renal Denervation Devices)市場動向(2012-2016)
    TechNavio's analysts forecast the Global Renal Denervation Devices market to grow at a CAGR of 41.74 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of hypertension. The Global Renal Denervation Devices market has also been witnessing the increasing demand for minimally invasive procedures. However, the presence of alternativ …
  • フィットネスバイクの世界市場2016-2020
    About the Exercise Bike Market Exercise bikes are a great option to increase stamina and are among the main fitness equipment in cardio fitness regimes. They are used by all level of exercisers, including beginners, intermediate, and advanced levels of users. Exercising bikes focus on strength training of the lower body, and the option to increase or decrease the resistance offered by the bike giv …
  • Quantel Medical SA:市場シェア分析
    Quantel Medical SA Market Share Analysis Summary GlobalData’s new report, “Quantel Medical SA Market Share Analysis” provides in-depth information on Quantel Medical SA’s market position in the different medical equipment markets it operates in. The report provides Quantel Medical SA market share information in two key market categories – Ophthalmic Diagnostic Equipment and Refractive Surgery Devi …
  • 小型原子力発電炉の分析:Analyzing Small Nuclear Power Reactors
    The global energy jigsaw is constantly and increasingly being rearranged with the nuclear power supply. Nuclear power is increasingly presenting an alternative to become the mainstay of energy needs for the new society till the time developments are further underway for cleaner energy sources. The harnessing of this energy would not have been possible without the inventing effort of Le? Szil?rd in …
  • 世界のウェアラブル医療技術市場動向(2012-2016)
    TechNavio's analysts forecast the Global Wearable Medical Technology market to grow at a CAGR of 49.94 percent over the period 2012-2016. One of the key factors contributing to this market growth is the technological innovations. The Global Wearable Medical Technology market has also been witnessing increasing strategic agreements among vendors. However, the instances of product recalls could pose …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。